Preliminary results validate real-world outcomes and continue to demonstrate TMS therapy is an important non-medication treatment option for depression
MALVERN, Pa., May 22, 2017 /PRNewswire/ — NeuroStar® Advanced Therapy, the established leader in transcranial magnetic stimulation (TMS), today announced its depression outcomes registry has exceeded 500 patients at approximately 50 treatment facilities in the United States. The NeuroStar outcomes registry is projected to grow from 500 to 6,000 patients by 2019, making it the largest registry of treatment-resistant depression. The data gathered during the initial six months found that the majority of patients (62%) treated with NeuroStar Advanced Therapy experienced significant improvement in their depression symptoms. The results from this outcomes study further validate real-world outcomes seen in an open-label clinical trial where 58% of patients experienced significant improvement, and 37% achieved remission of their depression symptoms.(1)
“I’m proud to be a part of this important depression outcomes registry. The NeuroStar Outcomes Registry helps me better understand and meet the needs of my patients, while also sharing critical information with other physicians so they can give their patients a chance for remission from chronic depression,” said Scott West, MD, Medical Director, ThriveLogic TMS + NeuroHealth. “These initial results affirm that non-medication treatments like NeuroStar Advanced Therapy should be seriously considered and evaluated by both patients and healthcare practitioners as a legitimate treatment option for anyone who has seen failures with prescription medicine.”
Approximately four and a half million people in the United States being treated for depression do not benefit from antidepressant medication.(2) With more than 1.4 million treatments delivered to date, NeuroStar Advanced Therapy was cleared by the FDA in 2008 as a safe and effective treatment for adult patients with MDD who have not seen success with at least one antidepressant medication. It is available by prescription and typically administered daily in a doctor’s office for four to six weeks. NeuroStar Advanced Therapy is improving patient access to this therapy with its widespread insurance coverage and enhanced scheduling convenience as the only FDA cleared TMS treatment that can be delivered in under 19 minutes. Additionally, there has been a 20 percent increase in the number of NeuroStar systems across the country in the past year. The non-drug, non-invasive treatment uses magnetic pulses to stimulate areas of the brain that are underactive in depression. It is not electroconvulsive therapy (ECT) and uses a different mechanism than ECT. Backed with the most clinical studies for TMS in depression,(1,3,4) NeuroStar Advanced Therapy is free from side effects often associated with antidepressants.(5)
“These initial results from NeuroStar Outcomes Registry continue to provide strong, real-world evidence for NeuroStar Advanced Therapy, substantiating results from clinical studies and further demonstrating the therapy’s effectiveness for people living with Major Depressive Disorder,” said David G. Brock, MD, Medical Director at Neuronetics, Inc. “These results serve as a powerful tool that will advance the understanding of NeuroStar as a proven, breakthrough treatment that is widely accessible and is truly transforming lives. Quite simply, NeuroStar Advanced Therapy is an important and convenient treatment option today in the U.S.”
NeuroStar Advanced Therapy, along with leading medical faculty, presented the initial key findings during educational symposia at the Clinical TMS Society Annual Meeting (May 19 – 20) and will also share in the company’s product theater at the American Psychiatric Association (APA) Annual Meeting (May 20 – 24) in San Diego. During the Clinical TMS Society Annual Meeting, the company also honored the pioneers of the outcomes registry — the participating physicians who were the first to join the registry and have been valuable contributors on the path to making this the largest depression patient database.
Visit www.NeuroStar.com for more information about NeuroStar Advanced Therapy and click here to locate a NeuroStar doctor.
About NeuroStar® Advanced Therapy
NeuroStar Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation. It is backed by the largest clinical data set for Major Depressive Disorder (MDD) of any TMS device. NeuroStar Advanced Therapy is the #1 physician-preferred TMS treatment for patients with MDD, and there are over 800 NeuroStar systems in 49 states.
With over 300 million covered lives, NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.
NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05).(3) The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head. Long term durability of effect has not been established in a randomized controlled trial.
For more information and full safety and prescribing information, visit www.NeuroStar.com.
NeuroStar®, NeuroStar® Advanced Therapy, NeuroStar TMS Therapy®, and TrakStar™ are registered trademarks of Neuronetics, Inc.
*Treatment time may vary depending on doctor’s recommendation.
1 Carpenter LL, et al. Depress Anxiety, (2012)
2 Kessler RC, et al. JAMA, (2003)
3 George MS, et al. Arch Gen Psychiatry, (2010)
4 O’Reardon JP, et al. Biological Psychiatry, (2007)
5 Janicak PG, et al. J Clin Psychiatry, (2008)
SOURCE: NeuroStar Advanced Therapy